Why Sarepta Therapeutics, Inc. (SRPT) Nosedived on Wednesday

Angelica Ballesteros

Thu, May 8, 2025, 2:01 AM 3 min read

We precocious published an nonfiction titled Why These 10 Firms Nosedived Today. In this article, we are going to instrumentality a look astatine wherever Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands against the different stocks.

The banal marketplace bounced backmost from the erstwhile day’s losses, with each large indices finishing higher arsenic investors cheered the cardinal bank's determination to support involvement rates unchanged.

On Wednesday afternoon, the Federal Reserve kept rates dependable astatine a scope of 4.25 percent to 4.5 percent, saying that it was not successful a hurry to chopped rates and could inactive “wait and see” the impacts of President Donald Trump’s tariff policies.

The Dow Jones rallied by 0.70 percent, the S&P 500 accrued by 0.43 percent, and the Nasdaq grew by 0.27 percent.

Beyond the large indices, bucked a broader marketplace optimism arsenic investors sold disconnected connected a bid of disappointing news.

To travel up with the list, we considered lone the stocks with a $2-billion marketplace capitalization and $5-million trading volume.

A laboratory technician successful a achromatic overgarment holding a microscope and examining a vial of biopharmaceuticals.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) nosedived by 21.45 percent connected Wednesday to extremity astatine $36.72 apiece aft reporting a disappointing net show successful the archetypal 4th of the year.

During the period, the institution swung to a nett nonaccomplishment of $447.5 cardinal from a $36.1 cardinal nett income successful the aforesaid play past year, contempt revenues jumping by 80 percent to $744.9 cardinal from $413.5 cardinal year-on-year, with the summation chiefly driven by a $241-million higher nett merchandise gross from Elevidys—a cistron therapy for Duchenne muscular dystrophy (DMD)—as a effect of its expanded statement support in June 2024.

Looking ahead, Sarepta Therapeutics, Inc. (NASDAQ:SRPT) said it expects little revenues for full-year 2025, astatine $2.3 cardinal to $2.6 cardinal versus the $2.9 cardinal to $3.1 cardinal arsenic expected previously.

Earlier this year, Sarepta Therapeutics, Inc. (NASDAQ:SRPT) reported that a young diligent succumbed to acute liver nonaccomplishment aft receiving the Sarepta Elevidys therapy. While the hazard has already been flagged connected the Elevidys label, acute liver injuries starring to decease person not been antecedently reported successful objective investigating oregon real-world usage of Elevidys.

Overall SRPT ranks 2nd on our database of Wednesday's worst performers. While we admit the imaginable of SRPT arsenic an investment, our condemnation lies successful the content that AI stocks clasp greater committedness for delivering higher returns and doing truthful wrong a shorter clip frame. There is an AI banal that went up since the opening of 2025, portion fashionable AI stocks mislaid astir 25%. If you are looking for an AI banal that is much promising than SRPT but that trades astatine little than 5 times its earnings, cheque retired our study astir this cheapest AI stock.